{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:31:57Z","timestamp":1793385117491,"version":"4.5.0"},"reference-count":241,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apjo.2026.100381","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:10:44Z","timestamp":1791562244000},"page":"100381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["International consensuses and guidelines on etiology, diagnosis, and treatment of Retinal Vein Occlusion (RVO) by the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), Asia-Pacific Vitreo-retina Society (APVRS) and Academia Retina Internationalis (ARI)"],"prefix":"10.1016","volume":"15","author":[{"given":"Danny S.C.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-045X","authenticated-orcid":false,"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-3003","authenticated-orcid":false,"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-4528","authenticated-orcid":false,"given":"Taraprasad","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mae-Lynn","family":"Bastion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Bakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyam","family":"Bajimaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-9682","authenticated-orcid":false,"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-1585","authenticated-orcid":false,"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Olof","family":"Hattenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1873-6959","authenticated-orcid":false,"given":"Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian H.C.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6428","authenticated-orcid":false,"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-5848","authenticated-orcid":false,"given":"Heng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8471-2766","authenticated-orcid":false,"given":"Nishant V.","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-6220","authenticated-orcid":false,"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-6039","authenticated-orcid":false,"given":"Dat Dang","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-7799","authenticated-orcid":false,"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-7028","authenticated-orcid":false,"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-7169","authenticated-orcid":false,"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-7058","authenticated-orcid":false,"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0362-7285","authenticated-orcid":false,"given":"Yasuo","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-5227","authenticated-orcid":false,"given":"Jost B.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib1","doi-asserted-by":"crossref","first-page":"100109","DOI":"10.1016\/j.apjo.2024.100109","article-title":"Current research and future strategies for the management of vision-threatening diabetic retinopathy.","volume":"13","author":"H","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study","volume":"114","author":"Smith","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib3","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib4","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.010427","article-title":"Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors","volume":"9","author":"Song","year":"2019","journal-title":"J Glob Health"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib6","first-page":"27","article-title":"Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases","volume":"1","author":"Green","year":"1981","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ophtha.2013.07.025","article-title":"Mortality in patients with central retinal vein occlusion","volume":"121","author":"Bertelsen","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib8","first-page":"34","article-title":"Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial","volume":"104","year":"1986","journal-title":"Branch Vein Occlusion Study Group Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib9","first-page":"1434","article-title":"A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion","volume":"102","year":"1995","journal-title":"Cent Vein Occlusion Study Group N Report Ophthalmol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib15","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100302","article-title":"BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale","volume":"3","author":"Hattenbach","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","article-title":"Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials","volume":"9","author":"Danzig","year":"2025","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2026.100381_bib19","unstructured":"Chaudhary V. Aflibercept 8 mg in macular edema following retinal vein occlusion: Week 64 results from the QUASAR trial. presented at: Presented at the Angiogenesis Meeting 2026, Virtual Edition,; February 7, 2026. 2026;"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archophthalmol.2010.193","article-title":"Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9","volume":"128","author":"Blodi","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib22","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.oret.2025.05.025","article-title":"Treatment Patterns and Long-term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database","volume":"9","author":"Ip","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib24","article-title":"Artificial intelligence for retinal diseases","volume":"13","author":"Lim","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila) Jul-Aug"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib25","article-title":"Natural Language Processing in medicine and ophthalmology: A review for the 21st-century clinician","volume":"13","author":"Rojas-Carabali","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila) Jul-Aug"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib26","article-title":"Understanding natural language: Potential application of large language models to ophthalmology","volume":"13","author":"Yang","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila) Jul-Aug"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib27","article-title":"Latest developments of generative artificial intelligence and applications in ophthalmology","volume":"13","author":"Feng","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila) Jul-Aug"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3928\/23258160-20251201-02","article-title":"Machine Learning to Predict Outcomes and Dosing Frequency With Aflibercept for Macular Edema Following Central Retinal Vein Occlusion","volume":"57","author":"Mehta","year":"2026","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"10.1016\/j.apjo.2026.100381_bib29","article-title":"Minocycline to treat central retinal vein occlusion","author":"C C","year":"2021","journal-title":"Clin identifier"},{"key":"10.1016\/j.apjo.2026.100381_bib30","article-title":"Minocycline to Treat Branch Retinal Vein Occlusion","author":"C C","year":"2022","journal-title":"Clin identifier"},{"key":"10.1016\/j.apjo.2026.100381_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1209527","article-title":"Caspase-9 inhibition confers stronger neuronal and vascular protection compared to VEGF neutralization in a mouse model of retinal vein occlusion","volume":"17","author":"Avrutsky","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apjo.2026.100381_bib32","unstructured":"Deng W.L. Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment. ClinicalTrialsgov ID NCT07133438."},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib33","first-page":"1152","article-title":"Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE\u2122 Study","volume":"63","author":"Dhoot","year":"2022","journal-title":"Invest Ophthalmol & Vis Sci"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100905","article-title":"Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility","volume":"6","author":"Park","year":"2026","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib36","article-title":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS)","volume":"14","author":"Ruamviboonsuk","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila) Jan-Feb"},{"key":"10.1016\/j.apjo.2026.100381_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An Adaptation of the RAND\/UCLA Modified Delphi Panel Method in the Time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0161-6420(86)33751-5","article-title":"Relative afferent pupillary defect in central retinal vein occlusion","volume":"93","author":"Servais","year":"1986","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100381_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/724780","article-title":"Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data","volume":"2014","author":"Kolar","year":"2014","journal-title":"J Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IJG.0000000000001134","article-title":"Incidence of Open-angle Glaucoma in Newly Diagnosed Retinal Vein Occlusion: A Nationwide Population-based Study","volume":"28","author":"Na","year":"2019","journal-title":"J Glaucoma"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/aos.14141","article-title":"Association of glaucoma with risk of retinal vein occlusion: A meta-analysis","volume":"97","author":"Yin","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib43","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib44","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0161-6420(83)34530-9","article-title":"Classification of central retinal vein occlusion","volume":"90","author":"Hayreh","year":"1983","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib46","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1111\/aos.14087","article-title":"Evaluation of retinal nonperfusion in branch retinal vein occlusion using wide-field optical coherence tomography angiography","volume":"97","author":"Shiraki","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib47","doi-asserted-by":"crossref","unstructured":"Lam, RF, Radke, NV, Bandello, FM, et al, International consensuses and guidelines on management of proliferative diabetic retinopathy (PDR) by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI)., Asia Pac J Ophthalmol (Phila), 2025, 14, 100262.","DOI":"10.1016\/j.apjo.2025.100262"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/IAE.0000000000004681","article-title":"FREQUENCY OF MISDIAGNOSES AND ASSOCIATED RISK FACTORS IN MACULAR TELANGIECTASIA TYPE 2","volume":"46","author":"Raming","year":"2026","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib49","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00006982-200509000-00012","article-title":"Retinal vascular occlusion in patients infected with human immunodeficiency virus","volume":"25","author":"Dunn","year":"2005","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.survophthal.2009.02.024","article-title":"Ocular ischemic syndrome","volume":"55","author":"Mendrinos","year":"2010","journal-title":"Surv Ophthalmol"},{"issue":"18","key":"10.1016\/j.apjo.2026.100381_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186014","article-title":"Retinal Microvascular Changes in Internal Carotid Artery Stenosis","volume":"12","author":"Batu Oto","year":"2023","journal-title":"J Clin Med"},{"issue":"14","key":"10.1016\/j.apjo.2026.100381_bib52","article-title":"Ocular Structural and Vascular Changes in Patients with Severe Asymptomatic Carotid Disease After Undergoing Carotid Endarterectomy (CEA) and Carotid Artery Stenting (CAS)","volume":"15","author":"Xanthou","year":"2025","journal-title":"Diagn (Basel)"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10792-025-03537-y","article-title":"Incidence of ocular ischemic syndrome in patients with asymptomatic severe internal carotid artery stenosis","volume":"45","author":"Hou","year":"2025","journal-title":"Int Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12348-024-00396-z","article-title":"Mimickers of anterior uveitis, scleritis and misdiagnoses- tips and tricks for the cornea specialist","volume":"14","author":"Caplash","year":"2024","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00131023","article-title":"The ocular ischemic syndrome. Clinical, fluorescein angiographic and carotid angiographic features","volume":"11","author":"Brown","year":"1988","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0161-6420(97)30221-8","article-title":"Ocular ischemic syndrome","volume":"104","author":"Mizener","year":"1997","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib57","first-page":"486","article-title":"Natural history and clinical management of central retinal vein occlusion","volume":"115","year":"1997","journal-title":"Cent Vein Occlusion Study Group Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.04.001","article-title":"Ocular vascular occlusive disorders: natural history of visual outcome","volume":"41","author":"Hayreh","year":"2014","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib59","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/archopht.1980.01020040452011","article-title":"Hemi-central retinal vein occulsion. Pathogenesis, clinical features, and natural history","volume":"98","author":"Hayreh","year":"1980","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(14)70001-7","article-title":"Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics","volume":"117","author":"Hayreh","year":"1994","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaophthalmol.2013.5515","article-title":"Branch retinal vein occlusion: natural history of visual outcome","volume":"132","author":"Hayreh","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/2008-322X.150825","article-title":"Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review","volume":"9","author":"DeCroos","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib63","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib64","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bjo.2005.068668","article-title":"WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward?","volume":"90","author":"Hossain","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"10266","key":"10.1016\/j.apjo.2026.100381_bib65","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal vascular occlusions","volume":"396","author":"Scott","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/1120672120909181","article-title":"Combined central retinal vein occlusion and branch retinal artery occlusion treated with intravitreal dexamethasone implant: A case report","volume":"31","author":"Arrigo","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib67","first-page":"434","article-title":"Simultaneous central retinal vein occlusion and branch retinal artery occlusion in a young patient with gout","volume":"6","author":"Kwok","year":"2015","journal-title":"J Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib68","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/IAE.0b013e31815ec29b","article-title":"Central retinal vein occlusion associated with cilioretinal artery occlusion","volume":"28","author":"Hayreh","year":"2008","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/ijo.IJO_340_16","article-title":"Combined branch retinal vein and branch retinal artery occlusion - clinical features, systemic associations, and outcomes","volume":"65","author":"Sengupta","year":"2017","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/09273948.2011.582219","article-title":"Branch retinal artery occlusion associated with Beh\u00e7et disease","volume":"19","author":"Yahia","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2017.6843","article-title":"Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial","volume":"136","author":"Scott","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib72","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9046781","article-title":"Evaluation of Microvascular Structure Changes after Conbercept Treatment on Macular Edema Secondary to Retinal Vein Occlusion","volume":"2020","author":"Song","year":"2020","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","article-title":"Natural history of visual outcome in central retinal vein occlusion","volume":"118","author":"Hayreh","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib74","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF02169451","article-title":"Electroretinography in central retinal vein occlusion. Correlation of electroretinographic changes with pupillary abnormalities","volume":"227","author":"Hayreh","year":"1989","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib75","first-page":"488","article-title":"Ocular neovascularization with retinal vascular occlusion-III","volume":"90","author":"Hayreh","year":"1983","journal-title":"Incid Ocul neovascularization Retin vein occlusion Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib76","article-title":"Sequential Observations of Conversion from Nonischemic to Ischemic Central Retinal Vein Occlusion Using Optical Coherence Tomography Angiography","volume":"2018","author":"Fukutomi","year":"2018","journal-title":"Case Rep Ophthalmol Med"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib77","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.oret.2022.03.012","article-title":"Association between Retinal Vein Occlusion and Life's Simple 7 Cardiovascular Health Metrics: A Large Claims Database Study","volume":"6","author":"Hashimoto","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib78","first-page":"e534","article-title":"Impact of cardiovascular risk factors on incidence and severity of Retinal Vein Occlusion","volume":"171","author":"Pacella","year":"2020","journal-title":"Clin Ter"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib79","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1167\/iovs.09-4453","article-title":"Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study","volume":"51","author":"Yasuda","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib80","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/archopht.126.5.692","article-title":"Retinal vein occlusion and traditional risk factors for atherosclerosis","volume":"126","author":"O'Mahoney","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib81","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2337\/dc08-0342","article-title":"Ocular associations of diabetes other than diabetic retinopathy","volume":"31","author":"Jeganathan","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib82","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archophthalmol.2011.2","article-title":"Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion","volume":"129","author":"Werther","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib83","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jcjo.2020.03.004","article-title":"Screening for obstructive sleep apnea amongst patients with retinal vein occlusion","volume":"55","author":"Felfeli","year":"2020","journal-title":"Can J Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib84","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archophthalmol.2010.272","article-title":"Obstructive sleep apnea among patients with retinal vein occlusion","volume":"128","author":"Glacet-Bernard","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib85","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2012.01.011","article-title":"Sleep apnea and risk of retinal vein occlusion: a nationwide population-based study of Taiwanese","volume":"154","author":"Chou","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib86","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1111\/aos.13798","article-title":"Retinal vein occlusion and obstructive sleep apnea: a series of 114 patients","volume":"96","author":"Agard","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2020.07.050","article-title":"Retinal Vein Occlusion and the Risk of Dementia: A Nationwide Cohort Study","volume":"221","author":"Nam","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00417-001-0421-3","article-title":"Hematologic abnormalities associated with various types of retinal vein occlusion","volume":"240","author":"Hayreh","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib89","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2006.06.061","article-title":"Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts","volume":"114","author":"Cugati","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib90","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0002-9394(14)74853-6","article-title":"Long-term follow-up of occlusion of the central retinal vein in young adults","volume":"90","author":"Priluck","year":"1980","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib91","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ajo.2007.07.015","article-title":"Retinal vein occlusions and mortality: the Beijing Eye Study","volume":"144","author":"Xu","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib92","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ophtha.2025.02.007","article-title":"Incidence of Retinal Vein Occlusion and Its Association with Mortality: Results from the Gutenberg Health Study","volume":"132","author":"Voigt","year":"2025","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib93","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","article-title":"Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies","volume":"112","author":"Wong","year":"2005","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib94","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004703","article-title":"Impact of Retinal Vein Occlusion on Stroke Incidence: A Meta-Analysis","volume":"5","author":"Li","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"Pt 6","key":"10.1016\/j.apjo.2026.100381_bib95","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/eye.2000.230","article-title":"Nine year follow-up study of morbidity and mortality in retinal vein occlusion","volume":"14","author":"Tsaloumas","year":"2000","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib96","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2008.08.006","article-title":"Retinal vein occlusion and the risk of stroke development: a five-year follow-up study","volume":"147","author":"Ho","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/aos.13214","article-title":"No evidence for thrombophilia in patients with retinal venous occlusion: a systematic GRADE-based review","volume":"95","author":"Kirkegaard","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib98","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1111\/jth.15068","article-title":"Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis","volume":"18","author":"Romiti","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.apjo.2026.100381_bib99","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jfo.2022.07.024","article-title":"Branch retinal vein occlusion secondary to hormone replacement therapy in a transgender woman","volume":"46","author":"Andzembe","year":"2023","journal-title":"J Fr Ophtalmol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib101","first-page":"549","article-title":"M. Combined central retinal vein occlusion and cilioretinal artery occlusion in a patient on hormone replacement therapy","volume":"84","author":"Christopoulou","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"Pt 6","key":"10.1016\/j.apjo.2026.100381_bib102","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/eye.1999.236","article-title":"Hormone replacement therapy and retinal vein occlusion","volume":"13","author":"Cahill","year":"1999","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2026.100381_bib103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2025.05.027","article-title":"Hormonal Contraception and Retinal Vascular Occlusion Risk","volume":"277","author":"Niazi","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib104","article-title":"Hormone replacement therapies and retinal disease: A systematic review and meta-analysis","volume":"3","author":"Rahat Qureshi","year":"2026","journal-title":"AJO Int"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaophthalmol.2020.4884","article-title":"Association of Retinal Vascular Occlusion With Women Filling a Prescription for Female Hormone Therapy","volume":"139","author":"Song","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib106","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/eye.2015.164","article-title":"The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary","volume":"29","author":"Sivaprasad","year":"2015","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib107","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib108","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib109","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"issue":"38","key":"10.1016\/j.apjo.2026.100381_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25380","article-title":"Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT","volume":"25","author":"Hykin","year":"2021","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.apjo.2026.100381_bib112","unstructured":"Eylea HD\u00ae (aflibercept) injection 8 MG phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion. Regeneron Pharmaceuticals Inc. December 17, 2025. Accessed January 9, 2025. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylea-hdr-aflibercept-injection-8-mg-phase-3-trial-meets-primary."},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib113","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.oret.2024.04.014","article-title":"Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!","volume":"8","author":"Alforja","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib114","first-page":"1178","article-title":"Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry","volume":"106","author":"Hunt","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.oret.2022.11.001","article-title":"Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry","volume":"7","author":"Hunt","year":"2023","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib116","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40123-023-00830-w","article-title":"Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study","volume":"13","author":"Giocanti-Aur\u00e9gan","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib117","doi-asserted-by":"crossref","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3129\/can j ophthalmol.06-101","article-title":"Role of inflammation in retinal vein occlusion","volume":"42","author":"Lee","year":"2007","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib119","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"Scott","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ophtha.2010.11.020","article-title":"SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion","volume":"118","author":"Chan","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib121","first-page":"2821","article-title":"Effect of posterior sub-tenon triamcinolone in macular edema due to non-ischemic vein occlusions","volume":"7","author":"Gurram","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.apjo.2026.100381_bib122","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2147\/OPTH.S170562","article-title":"Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein occlusion","volume":"12","author":"Tsai","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/01.iae.0000237584.56552.1c","article-title":"Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide","volume":"27","author":"Lin","year":"2007","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib124","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1111\/aos.13770","article-title":"Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study","volume":"96","author":"Feltgen","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"15","key":"10.1016\/j.apjo.2026.100381_bib125","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1038\/s41433-023-02488-x","article-title":"Outcomes in patients with retinal vein occlusion with good baseline visual acuity","volume":"37","author":"Liu","year":"2023","journal-title":"Eye (Lond)"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib126","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1097\/IAE.0000000000004244","article-title":"GOOD INITIAL VISUAL ACUITY IN PATIENTS WITH MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION: Management and Outcomes","volume":"44","author":"Gomel","year":"2024","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41433-025-04089-2","article-title":"Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study","volume":"40","author":"Dinah","year":"2026","journal-title":"Eye (Lond)"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib128","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.4103\/ijo.IJO_1330_22","article-title":"Long-term real-world outcomes in retinal vein occlusions: How close are we to the trials?","volume":"70","author":"Shah","year":"2022","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12886-020-01757-7","article-title":"Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab","volume":"21","author":"Narayanan","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/OPTH.S515479","article-title":"CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib131","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-026-00872-9","article-title":"Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects","volume":"12","author":"Zong","year":"2026","journal-title":"Int J Retin Vitr"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib132","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1097\/IAE.0000000000000191","article-title":"Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial","volume":"34","author":"Brown","year":"2014","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib133","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study","volume":"124","author":"Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib134","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/s41433-021-01833-2","volume":"36","author":"Bhambra","year":"2022","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib135","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ophtha.2017.01.049","article-title":"Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial","volume":"124","author":"Wykoff","year":"2017","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib136","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","article-title":"Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib137","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00417-013-2528-8","article-title":"Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)","volume":"252","author":"Rehak","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100381_bib138","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.3928\/23258160-20181101-19","article-title":"Navigated Retina Laser Therapy as a Novel Method for Laser Retinopexy of Retinal Tears","volume":"49","author":"Gologorsky","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-017-0077-7","article-title":"A Review of Subthreshold Micropulse Laser and Recent Advances in Retinal Laser Technology","volume":"6","author":"Su","year":"2017","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib140","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ophtha.2006.05.056","article-title":"Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser","volume":"113","author":"Parodi","year":"2006","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib141","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00417-014-2845-6","article-title":"Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment","volume":"253","author":"Parodi","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100381_bib142","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4103\/IJO.IJO_1081_25","article-title":"Role of subthreshold micropulse photocoagulation using 532 nm green laser for persistent macular edema secondary to branch retinal vein occlusion","volume":"73","author":"Sharma","year":"2025","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071394","article-title":"Subthreshold Diode Micropulse Laser Combined with Intravitreal Therapy for Macular Edema-A Systematized Review and Critical Approach","volume":"10","author":"Gaw\u0119cki","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib144","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/APO.0000000000000286","article-title":"Chorioretinal Anastomosis for Central Retinal Vein Occlusion: A Review of Its Development, Technique, Complications, and Role in Management","volume":"9","author":"McAllister","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila) May-Jun"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archopht.116.1.43","article-title":"D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion","volume":"116","author":"Goldberg","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib146","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(98)00156-1","article-title":"Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors","volume":"126","author":"McAllister","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib147","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/archopht.1995.01100040072030","article-title":"Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion","volume":"113","author":"McAllister","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib148","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jamaophthalmol.2018.4973","article-title":"Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion: A Randomized Clinical Trial","volume":"136","author":"McAllister","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib149","first-page":"216","article-title":"Vitreous hemorrhage and fibrovascular proliferation after laser-induced chorioretinal venous anastomosis","volume":"4","author":"Shiraya","year":"2011","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00417-008-0980-7","article-title":"Physiology of vitreous surgery","volume":"247","author":"Stef\u00e1nsson","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib151","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17425255.2018.1416098","article-title":"The study of intravitreal drug pharmacokinetics: does it matter? and if so, how?","volume":"14","author":"Stewart","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib152","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/17425255.2017.1404987","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes","volume":"13","author":"Edington","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apjo.2026.100381_bib153","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/OPTH.S73265","article-title":"Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye","volume":"8","author":"Hahn","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib154","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00006982-200603000-00008","article-title":"Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases","volume":"26","author":"Opremcak","year":"2006","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00417-012-2134-1","article-title":"A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group","volume":"251","author":"Aggermann","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib156","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000314716","article-title":"Radial optic neurotomy in central retinal vein occlusion does not influence ocular hemodynamics","volume":"225","author":"Skevas","year":"2011","journal-title":"Ophthalmologica"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib157","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1097\/IAE.0b013e3181d8e7e8","article-title":"Central retinal vessel blood flow after surgical treatment for central retinal vein occlusion","volume":"30","author":"Crama","year":"2010","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib158","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/bjo.2004.048181","article-title":"Radial optic neurotomy for ischaemic central vein occlusion","volume":"89","author":"Mart\u00ednez-Jard\u00f3n","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib159","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00417-006-0501-5","article-title":"Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases","volume":"245","author":"Hasselbach","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib160","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0002-9394(03)00698-6","article-title":"Radial optic neurotomy as treatment for central retinal vein occlusion","volume":"136","author":"Weizer","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib161","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0b013e3181744153","article-title":"Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"28","author":"Arevalo","year":"2008","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib162","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00006982-200212000-00009","article-title":"Vitrectomy with arteriovenous decompression and internal limiting membrane dissection in branch retinal vein occlusion","volume":"22","author":"Mester","year":"2002","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199901000-00001","article-title":"Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases","volume":"19","author":"Opremcak","year":"1999","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib164","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00417-008-0830-7","article-title":"Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion","volume":"246","author":"Chung","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00055735-200006000-00003","article-title":"Adventitial sheathotomy for treatment of macular edema associated with branch retinal vein occlusion","volume":"11","author":"Shah","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib166","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1600-0420.2007.00998.x","article-title":"Sheathotomy in complicated cases of branch retinal vein occlusion","volume":"86","author":"Crafoord","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"20","key":"10.1016\/j.apjo.2026.100381_bib167","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial","volume":"317","author":"Scott","year":"2017","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib168","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39303-2","article-title":"Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion","volume":"13","author":"Chung","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib169","doi-asserted-by":"crossref","first-page":"e1199","DOI":"10.1111\/aos.15068","article-title":"Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis","volume":"100","author":"Nanji","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3928\/23258160-20230221-04","article-title":"Safety and Efficacy of a Treat-and-Extend Regimen of Anti-Vascular Endothelial Growth Factor Agents for Diabetic Macular Edema or Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis","volume":"54","author":"Patil","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"33","key":"10.1016\/j.apjo.2026.100381_bib171","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043931","article-title":"Comparing the effectiveness of treating branch retinal vein occlusion with a novel one and stepped pro re nata treatment protocol","volume":"104","author":"Chen","year":"2025","journal-title":"Med (Baltim)"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib172","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","article-title":"Retinal vein occlusion (RVO) guideline: executive summary","volume":"36","author":"Nicholson","year":"2022","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib173","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000539648","article-title":"The Association between Retinal Thickness Fluctuations and Visual Outcomes under Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-Analysis","volume":"247","author":"Pandya","year":"2024","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib174","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/10807683251380974","article-title":"Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials","volume":"42","author":"Rassi","year":"2026","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.apjo.2026.100381_bib175","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5948113","article-title":"Effect of Alternate Treatment with Intravitreal Corticosteroid and Anti-VEGF for Macular Edema Secondary to Retinal Vein Occlusion","volume":"2021","author":"Bae","year":"2021","journal-title":"J Ophthalmol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100381_bib176","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.18240\/ijo.2024.10.09","article-title":"SL. Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion","volume":"17","author":"Zhong","year":"2024","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib177","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaophthalmol.2018.6111","article-title":"Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study","volume":"137","author":"Ip","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib178","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1177\/1120672120978355","article-title":"The efficacy of dexamethasone implants following anti-VEGF failure for macular oedema in retinal vein occlusion","volume":"31","author":"Yap","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib179","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.APO.0000617924.11529.88","article-title":"Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion","volume":"9","author":"Spooner","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila) Jan-Feb"},{"issue":"20","key":"10.1016\/j.apjo.2026.100381_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14207197","article-title":"Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results","volume":"14","author":"Hafner","year":"2025","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib181","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1111\/aos.12255","article-title":"Dexamethasone tachyphylaxis in the treatment of macular oedema","volume":"92","author":"Parodi","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib182","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.oret.2019.02.010","article-title":"Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies","volume":"3","author":"Feltgen","year":"2019","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib183","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09286586.2020.1792937","article-title":"Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion","volume":"28","author":"Hogg","year":"2021","journal-title":"Ophthalmic Epidemiol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib184","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00417-020-05018-7","article-title":"Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents: SCORE2 report 12: secondary analysis of the SCORE2 clinical trial","volume":"259","author":"Khurana","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib185","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00417-023-05989-3","article-title":"Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study","volume":"261","author":"Grimm","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib186","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/jovr.jovr_264_17","article-title":"Optical Coherence Tomography Angiography in Eyes with Retinal Vein Occlusion","volume":"13","author":"Tsai","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.apjo.2026.100381_bib187","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2017.07.015","article-title":"Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion","volume":"182","author":"Nicholson","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100381_bib188","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.927782","article-title":"Wide-Field Fluorescein Angiography in the Diagnosis and Management of Retinal Vein Occlusion: A Retrospective Single-Center Study","volume":"27","author":"Turczy\u0144ska","year":"2021","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib189","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/IAE.0b013e3181e36c6d","article-title":"Ischemic index and neovascularization in central retinal vein occlusion","volume":"31","author":"Tsui","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2026.100381_bib190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/OPTH.S125486","article-title":"Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion","volume":"11","author":"Abri Aghdam","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib191","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/bjophthalmol-2017-311475","article-title":"Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study","volume":"102","author":"Kwon","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100381_bib192","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/IAE.0000000000000148","article-title":"Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion","volume":"34","author":"Singer","year":"2014","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib193","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4103\/ijo.IJO_1364_18","article-title":"Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema","volume":"67","author":"Goel","year":"2019","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib194","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1111\/aos.12721","article-title":"Comparative study of combined bevacizumab\/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions","volume":"94","author":"Tomomatsu","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib195","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3928\/23258160-20150610-04","article-title":"Reliability of Ischemic Index Grading in Common Retinal Vascular Diseases","volume":"46","author":"Tsui","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib196","first-page":"94","article-title":"Deep-learning classifier with ultrawide-field fundus ophthalmoscopy for detecting branch retinal vein occlusion","volume":"12","author":"Nagasato","year":"2019","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18240\/ijo.2024.01.01","article-title":"WH. Intelligent diagnosis of retinal vein occlusion based on color fundus photographs","volume":"17","author":"Ji","year":"2024","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib198","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.18240\/ijo.2021.12.13","article-title":"Artificial intelligence can assist with diagnosing retinal vein occlusion","volume":"14","author":"Chen","year":"2021","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib199","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mp.16012","article-title":"Assessing retinal vein occlusion based on color fundus photographs using neural understanding network (NUN)","volume":"50","author":"Beeche","year":"2023","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib200","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61561-x","article-title":"Deep learning segmentation of non-perfusion area from color fundus images and AI-generated fluorescein angiography","volume":"14","author":"Masayoshi","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib201","doi-asserted-by":"crossref","DOI":"10.2196\/28868","article-title":"A Multimodal Imaging-Based Deep Learning Model for Detecting Treatment-Requiring Retinal Vascular Diseases: Model Development and Validation Study","volume":"9","author":"Kang","year":"2021","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.apjo.2026.100381_bib202","article-title":"Artificial intelligence based retinal imaging for cardiovascular risk and statin guidance in retinal vein occlusion","volume":"26","author":"Nam","year":"2026","journal-title":"Am J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100381_bib203","article-title":"The Role of Artificial Intelligence in the Diagnosis, Segmentation, and Prediction of Retinal Vein Occlusion: A Systematic Review","volume":"17","author":"Maliagkani","year":"2025","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib204","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/IAE.0b013e3181a3b870","article-title":"Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion","volume":"29","author":"Hattenbach","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2026.100381_bib205","first-page":"471","article-title":"Thrombolytic therapy for central retinal vein occlusion: results of a pilot study","volume":"94","author":"Elman","year":"1996","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib206","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/00006982-200312000-00006","article-title":"Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion","volume":"23","author":"Ghazi","year":"2003","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib207","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ajo.2008.06.016","article-title":"Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion","volume":"146","author":"Hattenbach","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib208","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/S0161-6420(01)00875-2","article-title":"Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion","volume":"108","author":"Weiss","year":"2001","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib209","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ophtha.2006.06.064","article-title":"Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study","volume":"114","author":"Feltgen","year":"2007","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/aos.12830","article-title":"Updated cannulation technique for tissue plasminogen activator injection into peripapillary retinal vein for central retinal vein occlusion","volume":"93","author":"van Overdam","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100381_bib211","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bjo.73.11.895","article-title":"A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution","volume":"73","author":"Hansen","year":"1989","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib212","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00176435","article-title":"Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study","volume":"232","author":"Wolf","year":"1994","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib213","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000369566","article-title":"Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial","volume":"233","author":"Kreutzer","year":"2015","journal-title":"Ophthalmologica"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib214","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1167\/iovs.13-13676","article-title":"Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice","volume":"55","author":"Chou","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib215","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s13063-022-06527-y","article-title":"HORNBILL: a phase I\/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol","volume":"23","author":"Chong","year":"2022","journal-title":"Trials"},{"issue":"18","key":"10.1016\/j.apjo.2026.100381_bib216","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41433-025-03835-w","article-title":"New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A\/Nrp1 pathway","volume":"39","author":"Sivaprasad","year":"2025","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100781","article-title":"HORNBILL: A First-in-Human Phase I\/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia","volume":"5","author":"Nguyen","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib218","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2007.01.010","article-title":"Interventions for branch retinal vein occlusion: an evidence-based systematic review","volume":"114","author":"McIntosh","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib219","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ophtha.2006.11.011","article-title":"Interventions for central retinal vein occlusion: an evidence-based systematic review","volume":"114","author":"Mohamed","year":"2007","journal-title":"Ophthalmology"},{"issue":"26","key":"10.1016\/j.apjo.2026.100381_bib220","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia","volume":"95","author":"Yrj\u00e4nheikki","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.apjo.2026.100381_bib221","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.exer.2013.05.018","article-title":"Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion","volume":"113","author":"Sun","year":"2013","journal-title":"Exp Eye Res"},{"issue":"12","key":"10.1016\/j.apjo.2026.100381_bib222","article-title":"H. Minocycline Inhibits Microglial Activation and Improves Visual Function in a Chronic Model of Age-Related Retinal Degeneration","volume":"10","author":"Byrne","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib223","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2004.tb00081.x","article-title":"Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats","volume":"14","author":"Maier","year":"2004","journal-title":"Brain Pathol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib224","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.exer.2006.05.019","article-title":"CNTF gene transfer protects ganglion cells in rat retinae undergoing focal injury and branch vessel occlusion","volume":"83","author":"MacLaren","year":"2006","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib225","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41467-020-14821-z","article-title":"Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment","volume":"11","author":"Kang","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.apjo.2026.100381_bib226","first-page":"3233","article-title":"ANXV (a human recombinant Annexin A5) is well-tolerated and safe in Phase 1 First In Human clinical trial and is currently in Phase 2 in Retinal Vein Occlusion","volume":"64","author":"Frostegaard","year":"2023","journal-title":"Invest Ophthalmol & Vis Sci"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib227","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antiox15030338","article-title":"Pathophysiological Roles of Oxidative Stress and the Translational Potential of Antioxidant Therapy in Retinal Vein Occlusion","volume":"15","author":"Noma","year":"2026","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib228","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s10792-025-03687-z","article-title":"Exploring the role of oxidative stress in retinal vein occlusion: an updated and comprehensive review on the pathophysiology and treatment perspectives","volume":"45","author":"Zhang","year":"2025","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100381_bib229","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/db06-1254","article-title":"Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells","volume":"56","author":"Caballero","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.apjo.2026.100381_bib230","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib231","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/24741264241275271","article-title":"Suprachoroidal Triamcinolone Acetonide Injection to Treat Macular Edema: A Review","volume":"8","author":"Rahman","year":"2024","journal-title":"J Vitreoretin Dis"},{"issue":"7","key":"10.1016\/j.apjo.2026.100381_bib232","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100381_bib233","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-023-02808-5","article-title":"Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study","volume":"23","author":"Ali","year":"2023","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib234","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/IAE.0000000000004688","article-title":"EFFICACY AND SAFETY OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE IN MIXED ETIOLOGY NONINFECTIOUS CYSTOID MACULAR EDEMA","volume":"46","author":"Prasad","year":"2026","journal-title":"Retina"},{"issue":"38","key":"10.1016\/j.apjo.2026.100381_bib235","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044647","article-title":"Resolution of lamellar macular hole after suprachoroidal triamcinolone injections for cystoid macular edema caused by retinal vein occlusion: A case report","volume":"104","author":"Abu Ghedda","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.apjo.2026.100381_bib236","first-page":"8","author":"Wykoff","year":"2021","journal-title":"Intravitreal Gene Therapy Diabetic Macular Edema ADVM-022 First Time Data Presentation Prospective Randomized Phase 2 INFINITY Trial"},{"issue":"6","key":"10.1016\/j.apjo.2026.100381_bib237","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaophthalmol.2023.1463","article-title":"Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial","volume":"141","author":"Kymes","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100381_bib238","doi-asserted-by":"crossref","first-page":"A177","DOI":"10.1016\/j.jval.2013.03.891","article-title":"Cost-Effectiveness Of Dexamethasone Intravitreal Implant In The Treatment Of Macular Edema (ME) Following Central Retinal Vein Occlusion (CRVO)","volume":"16","author":"Vicente","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.apjo.2026.100381_bib239","unstructured":"Clearside Biomedical announces SAPPHIRE Phase 3 study of combination therapy in retinal vein occlusion did not meet its primary endpoint. Clearside Biomedical, Inc.; November 5, 2018. Accessed Sep 10, 2026."},{"issue":"2","key":"10.1016\/j.apjo.2026.100381_bib240","first-page":"130","article-title":"Bilateral central retinal vein occlusion in a pregnant lady","volume":"72","author":"Loh","year":"2017","journal-title":"Med J Malays"},{"issue":"5","key":"10.1016\/j.apjo.2026.100381_bib241","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/ICB.0000000000001063","article-title":"CENTRAL RETINAL VEIN OCCLUSION WITH SEVERE MACULAR EDEMA IN EARLY PREGNANCY","volume":"16","author":"Pokroy","year":"2022","journal-title":"Retin Cases Brief Rep"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:51:43Z","timestamp":1793382703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":241,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162098926001076"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100381","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International consensuses and guidelines on etiology, diagnosis, and treatment of Retinal Vein Occlusion (RVO) by the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), Asia-Pacific Vitreo-retina Society (APVRS) and Academia Retina Internationalis (ARI)","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100381"}}